Simple, tangible steps taken by the UK and Danish governments to systematically improve their clinical trial environment offer rich learnings for Ireland, which is facing a steady decline in industry-sponsored studies.
As Ireland looks to reform its clinical trials processes to get a grip on the downward spiral of industry-sponsored studies, it could learn a lot from the changes that are being made, or have been successfully implemented, in the UK and Denmark to improve their respective research frameworks.
Suggestions to this end were made at a webinar organized on 11 June by the Irish Pharmaceutical Healthcare Association (IPHA),...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
